EM900

EM900 is a novel 12-membered non-antibiotic macrolide derived from erythromycin A, designed to retain potent anti-inflammatory and immunomodulatory effects without antibacterial activity[1][5]. Its mechanism of action involves the suppression of proinflammatory cytokines (e.g., IL-6, IL-13, IL-5, RANTES, IL-17A, MIP-2, IL-1β, MCP-1) and inhibition of NF-κB and p38 phosphorylation in macrophages, which attenuates airway inflammation in both type 2 (eosinophilic) and non-type 2 (neutrophilic) models[1]. EM900 also inhibits mucus hypersecretion (MUC5AC) from airway epithelial cells, further supporting its anti-inflammatory profile[5]. In the context of rhinovirus infection, EM900 reduces viral titers and cytokine secretion in epithelial cells, possibly by decreasing ICAM-1 expression and interfering with endosomal acidification required for viral entry[2]. EM900 is considered a promising candidate for chronic airway inflammatory diseases (e.g., asthma, chronic rhinosinusitis, COPD) due to its lack of antibiotic activity and thus no risk of promoting bacterial resistance[1][5]. Despite promising preclinical results, there is no evidence of clinical trials or approved use in humans as of the latest available data. No specific developer or manufacturer is identified in the literature.